[{"id":"b0107240-c9ff-4b67-b853-211b0d9cdc8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07469774","created_at":"2026-03-28T01:44:13.768Z","updated_at":"2026-03-28T01:44:13.768Z","phase":"Phase 1/2","brief_title":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT07469774","lead_sponsor":"Biocity Biopharmaceutics Co., Ltd.","biomarkers":" EGFR • BRAF • ALK • MET • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • BRAF • ALK • MET • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 03/17/2026","start_date":" 03/17/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2026-03-13"},{"id":"b44521d2-5829-4bf3-b6c2-ad08cfcaf642","acronym":"","url":"https://clinicaltrials.gov/study/NCT06863805","created_at":"2025-07-19T14:06:15.287Z","updated_at":"2025-07-19T14:06:15.287Z","phase":"","brief_title":"Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas","source_id_and_acronym":"NCT06863805","lead_sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","biomarkers":" BRAF • ALK • RET • RAS • NTRK","pipe":" | ","alterations":" RAS mutation • RET mutation","tags":["BRAF • ALK • RET • RAS • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation • RET mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-03-07"},{"id":"0db89e9b-db2b-43cc-83d7-77deb9d111cd","acronym":"SCOUT","url":"https://clinicaltrials.gov/study/NCT02637687","created_at":"2021-01-17T17:20:37.992Z","updated_at":"2025-02-25T12:26:24.234Z","phase":"Phase 1/2","brief_title":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children","source_id_and_acronym":"NCT02637687 - SCOUT","lead_sponsor":"Bayer","biomarkers":" NTRK3 • ETV6 • NTRK","pipe":" | ","alterations":" NTRK positive • NTRK fusion","tags":["NTRK3 • ETV6 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Vitrakvi (larotrectinib) • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 12/16/2015","start_date":" 12/16/2015","primary_txt":" Primary completion: 07/20/2024","primary_completion_date":" 07/20/2024","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-24"},{"id":"722e7e39-2b2e-4e81-be40-58b1e321be96","acronym":"","url":"https://clinicaltrials.gov/study/NCT06043713","created_at":"2023-09-21T15:10:30.740Z","updated_at":"2025-02-25T13:41:44.027Z","phase":"Phase 1","brief_title":"Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations","source_id_and_acronym":"NCT06043713","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK","pipe":" | ","alterations":" KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion","tags":["HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 12/15/2023","start_date":" 12/15/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 02/09/2026","study_completion_date":" 02/09/2026","last_update_posted":"2025-02-21"},{"id":"258815b3-da9e-48e7-8a38-615cfaef4dbd","acronym":"TROPION-Lung02","url":"https://clinicaltrials.gov/study/NCT04526691","created_at":"2021-01-18T21:40:42.295Z","updated_at":"2025-02-25T14:07:50.610Z","phase":"Phase 1","brief_title":"Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)","source_id_and_acronym":"NCT04526691 - TROPION-Lung02","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • KRAS • BRAF • ALK • ROS1 • PD-L2 • NTRK • TACSTD2","pipe":" | ","alterations":" KRAS mutation","tags":["EGFR • KRAS • BRAF • ALK • ROS1 • PD-L2 • NTRK • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 09/15/2020","start_date":" 09/15/2020","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 04/15/2026","study_completion_date":" 04/15/2026","last_update_posted":"2025-02-19"},{"id":"6fa58343-5f41-4e65-b9b7-ed2e1d17361f","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06116682","created_at":"2023-11-03T20:12:32.614Z","updated_at":"2025-02-25T14:10:16.796Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06116682 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/19/2024","start_date":" 11/19/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-19"},{"id":"204cae00-5d2c-422e-af6c-ba51e68ea377","acronym":"CONNECT1903","url":"https://clinicaltrials.gov/study/NCT04655404","created_at":"2021-01-19T20:41:28.986Z","updated_at":"2025-02-25T14:15:44.274Z","phase":"Phase 1","brief_title":"A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma with NTRK Fusion","source_id_and_acronym":"NCT04655404 - CONNECT1903","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/08/2021","start_date":" 04/08/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-18"},{"id":"fc32aaa3-7f5b-404e-9923-86b9a8cde5d8","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06031688","created_at":"2023-09-11T16:10:36.199Z","updated_at":"2025-02-25T14:10:03.191Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06031688 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cyramza (ramucirumab) • Tepmetko (tepotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 08/08/2024","start_date":" 08/08/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2025-02-17"},{"id":"a1cc20b7-e120-4c96-ad2e-1583010cd20c","acronym":"CARE study","url":"https://clinicaltrials.gov/study/NCT04094610","created_at":"2021-01-18T20:02:04.781Z","updated_at":"2025-02-25T14:40:19.057Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","source_id_and_acronym":"NCT04094610 - CARE study","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/12/2020","start_date":" 03/12/2020","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-14"},{"id":"9e22f735-9f0d-4c3a-92fb-91f43ae1a4bd","acronym":"TROPION-LUNG01","url":"https://clinicaltrials.gov/study/NCT04656652","created_at":"2021-01-19T20:41:43.327Z","updated_at":"2025-02-25T14:59:32.426Z","phase":"Phase 3","brief_title":"Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)","source_id_and_acronym":"NCT04656652 - TROPION-LUNG01","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • PD-L1 • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET exon 14 mutation","tags":["EGFR • PD-L1 • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 590","initiation":"Initiation: 12/21/2020","start_date":" 12/21/2020","primary_txt":" Primary completion: 05/10/2024","primary_completion_date":" 05/10/2024","study_txt":" Completion: 06/21/2025","study_completion_date":" 06/21/2025","last_update_posted":"2025-02-13"},{"id":"de85007a-8a96-4d92-b410-2aebe8f02c18","acronym":"","url":"https://clinicaltrials.gov/study/NCT06007924","created_at":"2023-08-23T15:11:08.435Z","updated_at":"2025-02-25T15:13:43.406Z","phase":"Phase 2","brief_title":"A Study of Avutometinib and Defactinib in People With Thyroid Cancer","source_id_and_acronym":"NCT06007924","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF • ALK • RET • NF1 • NTRK","pipe":" | ","alterations":" BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement","tags":["BRAF • ALK • RET • NF1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/16/2023","start_date":" 08/16/2023","primary_txt":" Primary completion: 08/16/2027","primary_completion_date":" 08/16/2027","study_txt":" Completion: 08/16/2027","study_completion_date":" 08/16/2027","last_update_posted":"2025-02-13"},{"id":"f02c2f2b-a093-410f-90e0-01cc532b5f16","acronym":"","url":"https://clinicaltrials.gov/study/NCT04786093","created_at":"2021-03-08T12:53:40.787Z","updated_at":"2025-02-25T15:11:58.304Z","phase":"Phase 2","brief_title":"Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC","source_id_and_acronym":"NCT04786093","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" PD-L1 • BRAF • ALK • ROS1 • PD-1 • CTLA4 • NTRK","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • ALK rearrangement • ROS1 fusion • NTRK fusion","tags":["PD-L1 • BRAF • ALK • ROS1 • PD-1 • CTLA4 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • ALK rearrangement • ROS1 fusion • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 07/27/2021","start_date":" 07/27/2021","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-13"},{"id":"393ae514-083b-4a6f-a6c0-c472fe56deef","acronym":"KEYNOTE-E59","url":"https://clinicaltrials.gov/study/NCT05083481","created_at":"2021-10-19T15:58:03.788Z","updated_at":"2025-02-25T15:19:18.701Z","phase":"Phase 1/2","brief_title":"A Study of ASP1570 Alone or in Combination With Pembrolizumab or Standard Therapies in Adults With Solid Tumors","source_id_and_acronym":"NCT05083481 - KEYNOTE-E59","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" EGFR • NTRK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • ALK positive • ALK mutation • NTRK fusion","tags":["EGFR • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • ALK positive • ALK mutation • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • docetaxel • Lonsurf (trifluridine/tipiracil) • ASP1570"],"overall_status":"Recruiting","enrollment":" Enrollment 310","initiation":"Initiation: 10/19/2021","start_date":" 10/19/2021","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-12"},{"id":"c0529000-1eea-42c3-9cae-d983a7189b6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05943795","created_at":"2023-07-13T18:10:45.267Z","updated_at":"2025-02-25T15:36:23.229Z","phase":"Phase 3","brief_title":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma","source_id_and_acronym":"NCT05943795","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • izalontamab (SI-B001)"],"overall_status":"Recruiting","enrollment":" Enrollment 584","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-11"},{"id":"1c1d3f40-f2af-499a-b04e-123bc4d694d0","acronym":"ON-TRK","url":"https://clinicaltrials.gov/study/NCT04142437","created_at":"2021-01-18T20:13:13.808Z","updated_at":"2025-02-25T15:26:13.445Z","phase":"","brief_title":"Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body","source_id_and_acronym":"NCT04142437 - ON-TRK","lead_sponsor":"Bayer","biomarkers":" NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 04/03/2020","start_date":" 04/03/2020","primary_txt":" Primary completion: 11/30/2029","primary_completion_date":" 11/30/2029","study_txt":" Completion: 03/31/2030","study_completion_date":" 03/31/2030","last_update_posted":"2025-02-10"},{"id":"a960e964-3a5f-401a-844c-ae8dd61b3da6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213704","created_at":"2023-12-06T19:15:43.766Z","updated_at":"2025-02-25T16:51:56.748Z","phase":"Phase 2","brief_title":"Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213704","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 08/23/2017","start_date":" 08/23/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 10/08/2025","study_completion_date":" 10/08/2025","last_update_posted":"2025-02-04"},{"id":"24c0fcb4-b357-4530-a6a0-668b57518e71","acronym":"ARC-27","url":"https://clinicaltrials.gov/study/NCT06120075","created_at":"2023-11-07T16:14:23.781Z","updated_at":"2025-02-25T17:32:32.864Z","phase":"Phase 1","brief_title":"A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies","source_id_and_acronym":"NCT06120075 - ARC-27","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" EGFR • PD-L1 • ALK • MET • RET • ROS1 • STK11 • NTRK","pipe":" | ","alterations":" EGFR mutation • STK11 mutation • ALK mutation","tags":["EGFR • PD-L1 • ALK • MET • RET • ROS1 • STK11 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • STK11 mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Yutuo (zimberelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 01/19/2024","start_date":" 01/19/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-01-30"},{"id":"d5544c15-13b5-44bf-a9ae-6f16815b81c0","acronym":"NTRK","url":"https://clinicaltrials.gov/study/NCT06780384","created_at":"2025-02-25T17:27:31.594Z","updated_at":"2025-02-25T17:27:31.594Z","phase":"","brief_title":"NTRK 1,2,3 Rearrangements in Patients With Solid Tumors","source_id_and_acronym":"NCT06780384 - NTRK","lead_sponsor":"Federico Cappuzzo","biomarkers":" NTRK","pipe":"","alterations":" ","tags":["NTRK"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 02/05/2020","start_date":" 02/05/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-01-17"},{"id":"49f30563-60f2-4168-9062-bb633cf7a950","acronym":"","url":"https://clinicaltrials.gov/study/NCT03994796","created_at":"2021-01-18T19:38:28.337Z","updated_at":"2025-02-25T14:28:26.216Z","phase":"Phase 2","brief_title":"Genetic Testing in Guiding Treatment for Patients with Brain Metastases","source_id_and_acronym":"NCT03994796","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" KRAS • BRAF • ER • PGR • ROS1 • NTRK","pipe":" | ","alterations":" HER-2 positive • EGFR mutation • HER-2 negative","tags":["KRAS • BRAF • ER • PGR • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • EGFR mutation • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib) • Verzenio (abemaciclib) • Krazati (adagrasib) • paxalisib (GDC-0084)"],"overall_status":"Recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 10/17/2019","start_date":" 10/17/2019","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-01-15"},{"id":"9019c921-3c37-404e-9dcf-6b18ca280688","acronym":"EPI VITRAKVI","url":"https://clinicaltrials.gov/study/NCT05236257","created_at":"2022-02-11T12:52:54.392Z","updated_at":"2025-02-25T17:12:08.743Z","phase":"","brief_title":"A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database","source_id_and_acronym":"NCT05236257 - EPI VITRAKVI","lead_sponsor":"Bayer","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 09/13/2022","primary_completion_date":" 09/13/2022","study_txt":" Completion: 09/13/2022","study_completion_date":" 09/13/2022","last_update_posted":"2024-12-10"},{"id":"245c1786-d5c4-49a7-8439-75f183f39949","acronym":"","url":"https://clinicaltrials.gov/study/NCT05783323","created_at":"2023-03-24T16:04:14.237Z","updated_at":"2025-02-25T17:26:04.484Z","phase":"Phase 2","brief_title":"Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer","source_id_and_acronym":"NCT05783323","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 02/14/2024","start_date":" 02/14/2024","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2024-11-12"},{"id":"2b6e1463-c371-4b17-a2c1-81d56ff0988e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03215511","created_at":"2021-01-18T15:52:01.409Z","updated_at":"2025-02-25T17:09:49.126Z","phase":"Phase 1","brief_title":"A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer","source_id_and_acronym":"NCT03215511","lead_sponsor":"Bayer","biomarkers":" NTRK3 • ETV6 • NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK3 • ETV6 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e selitrectinib (BAY 2731954)"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 07/03/2017","start_date":" 07/03/2017","primary_txt":" Primary completion: 04/11/2022","primary_completion_date":" 04/11/2022","study_txt":" Completion: 01/30/2023","study_completion_date":" 01/30/2023","last_update_posted":"2024-10-30"},{"id":"0cb9b398-2ca1-4b86-bddc-f169a1c4484d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04895982","created_at":"2021-05-21T12:52:53.997Z","updated_at":"2025-02-25T16:26:32.957Z","phase":"Phase 2","brief_title":"Study to Evaluate Safety, Tolerability \u0026 Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years","source_id_and_acronym":"NCT04895982","lead_sponsor":"BioNTech SE","biomarkers":" EGFR • BRAF • ROS1 • BCL2 • NTRK","pipe":"","alterations":" ","tags":["EGFR • BRAF • ROS1 • BCL2 • NTRK"],"overall_status":"Completed","enrollment":" Enrollment 124","initiation":"Initiation: 10/15/2021","start_date":" 10/15/2021","primary_txt":" Primary completion: 07/23/2023","primary_completion_date":" 07/23/2023","study_txt":" Completion: 07/23/2023","study_completion_date":" 07/23/2023","last_update_posted":"2024-10-09"},{"id":"3bc05eae-3b84-41fb-9cd4-422462f86a5a","acronym":"KEYNOTE-D65","url":"https://clinicaltrials.gov/study/NCT05462236","created_at":"2022-07-18T14:01:41.581Z","updated_at":"2025-02-25T16:17:56.790Z","phase":"Phase 2","brief_title":"MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05462236 - KEYNOTE-D65","lead_sponsor":"AUM Biosciences Pte Ltd","biomarkers":" EGFR • HER-2 • BRAF • MSI • NTRK","pipe":" | ","alterations":" BRAF V600E • MSI-H/dMMR • BRAF V600","tags":["EGFR • HER-2 • BRAF • MSI • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • MSI-H/dMMR • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • irinotecan • tinodasertib (AUM001)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 04/14/2023","start_date":" 04/14/2023","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 10/15/2026","study_completion_date":" 10/15/2026","last_update_posted":"2024-07-09"}]